SCHEMBL6893394

SCHEMBL6893394

Nc1c(Br)c(N2CCSCC2)nc2c(-c3cnc4ccccc4c3)cnn12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 6/20 0.37
CCNA2 P20248 6/20 0.37
CDK2 P24941 6/20 0.37
CCNA1 P78396 6/20 0.37
MEN1 O00255 5/20 0.36
NPC1 O15118 5/20 0.36
KMT2A Q03164 5/20 0.36
RAB9A P51151 4/20 0.36
BIRC5 O15392 1/20 0.36
EGFR P00533 3/20 0.35
FGFR2 P21802 3/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PDGFRB P09619 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7886529 0.90 NPC1 (0.37) MEN1NPC1KMT2ARAB9AEGFR
SCHEMBL6893430 0.88 NPC1 (0.44) MEN1NPC1KMT2ARAB9ASMN1; SMN2
SCHEMBL7879265 0.88 NPC1 (0.36) MEN1NPC1KMT2ARAB9AEGFR
SCHEMBL6891750 0.87 EGFR (0.36) CHEK1CCNA2CDK2CCNA1MEN1
SCHEMBL10234123 0.86 CHEK1 (0.37) CHEK1CCNA2CDK2CCNA1MEN1
SCHEMBL2680298 0.86 EGFR (0.40) MEN1NPC1KMT2ARAB9AEGFR
SCHEMBL6894370 0.86 ALDH1A1 (0.40) CHEK1CCNA2CDK2CCNA1MEN1
SCHEMBL6894323 0.85 NPC1 (0.41) MEN1NPC1KMT2ARAB9ASMN1; SMN2
SCHEMBL6893422 0.84 FGFR2 (0.40) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL6893777 0.84 CHEK1 (0.44) CHEK1CCNA2CDK2CCNA1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 CHEK1 2755/4885CCNA2 2265/4885CDK2 457/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.